The Ministry of Health (Ministerio de Sanidad) published its second report on the funding of innovative medicines in Spain on 18 February 2026. The analysis, covering the period from July 2020 to June 2024, reveals that the National Health System (Sistema Nacional de Salud) (SNS) now finances 78.8% of innovative medicines that formally request inclusion in the public pharmaceutical benefit. This represents a significant institutional shift in the capacity of the system to process and resolve therapeutic evaluations.
A central finding of the report is the reduction in administrative timelines. The median time from national registration to a financing decision has decreased by more than 50%, falling from 615 days in the 2020–2021 period to 303 days in the 2023–2024 cohort. The Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios) (AEMPS) has consolidated the initial registration process into a 42-day median timeframe, removing what was previously a significant bottleneck in the decision-making flow.
The report highlights the role of the Interministerial Commission on Medicines Prices (Comisión Interministerial de Precios de los Medicamentos) (CIPM) in balancing therapeutic value with financial sustainability. Decision-making authority rests with this collegial body, which includes representatives from the Ministry of Finance (Ministerio de Hacienda) and regional health authorities. Within this framework, 85.9% of funded medicines received a positive resolution in the first instance, suggesting greater predictability in the evaluation criteria applied by the CIPM.
Institutional mechanisms for early access have also proved effective. Over 57% of innovative medicines authorised in the European Union utilised the Medicines in Special Situations (Medicamentos en Situaciones Especiales) (MSE) pathway to reach patients before a final financing resolution. This mechanism has been particularly effective for orphan drugs, which saw a funding rate of 85.7% during the study period.
One measure that is more difficult to improve has been the total median time from European authorisation to Spanish funding. This remains at 503 days, largely due to commercial delays with one in six authorised products not immediately seeking a Spanish national code. This gap, often caused by manufacturers prioritising other markets or protecting international price tiers, inflates the time-to-funding metric.
Source: Ministry of Health.
Link: España financia cerca del 80% de los medicamentos innovadores que solicitan su inclusión en la prestación farmacéutica (Spain finances nearly 80% of innovative medicines that request inclusion in the pharmaceutical benefit).
Date: 18 February 2026